In the HEART-FID trial, researchers delved into the effectiveness and safety of intravenous ferric carboxymaltose (FCM) in the treatment of Heart Failure with Reduced Ejection Fraction (HFrEF). The trial included 3,065 HFrEF patients who were randomly assigned to one of two groups: those who received intravenous FCM (n=1,532) and those who received a placebo (n=1,533). After a 12-month follow-up period, the study revealed that all-cause mortality was 8.6% in the IV FCM group, compared to 10.3% in the placebo group. Additionally, hospitalization rates for heart failure were 13.3% for the IV FCM group and 14.8% for the placebo group. These findings were considered to demonstrate only a “marginal improvement.”
Learn more about the interesting studies presented at ESC Congress 2023.
For more cardiology research news join our newsletter or follow us on Twitter, Facebook, LinkedIn or Instagram.
